戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 iles for further study in different types of myocardial disease.
2 n of the regional changes in common advanced myocardial disease.
3 easures of function, suggestive of occult RV myocardial disease.
4  with Duchenne muscular dystrophy with early myocardial disease.
5 e to be an effective therapeutic strategy in myocardial disease.
6 icient forward cardiac output resulting from myocardial disease.
7 diseases including cancer, inflammation, and myocardial disease.
8 rt failure and implicate novel mechanisms of myocardial disease.
9 male; mean age, 48 years) without structural myocardial disease.
10  define the onset and molecular mechanism of myocardial disease.
11  (chromosome 1p1-1q1) cardiac conduction and myocardial disease.
12  (chromosome 1p1-1q1) cardiac conduction and myocardial disease.
13 are etiological agents of human inflammatory myocardial disease.
14 ion and the presence or absence of intrinsic myocardial disease.
15 ells (MSCs) have the potential to treat many myocardial diseases.
16  in oncology but has not yet been applied to myocardial diseases.
17 ), ischemic heart disease (91), infiltrative myocardial disease (59), hypertension (49), human immuno
18 ents with cardiomyopathy due to infiltrative myocardial disease (adjusted hazard ratio, 4.40; 95 perc
19 ation between E/E' and PCWP in patients with myocardial disease, an inverse relationship was found in
20 ardiac disease have evolved to conceptualize myocardial disease and patient vulnerability based on th
21  difficult to differentiate from restrictive myocardial disease and severe tricuspid regurgitation.
22 f constrictive pericarditis from restrictive myocardial disease and severe tricuspid regurgitation.
23  plays a central role in the pathogenesis of myocardial disease and that reactive oxygen species is c
24 o opens many possibilities for investigating myocardial disease and therapeutic intervention at the c
25          Early initiation greatly attenuated myocardial disease and, for the first time with these dr
26       These forces are affected by intrinsic myocardial disease but should be preserved when diastole
27 n-CMR imaging but showed clinically relevant myocardial disease by CMR imaging.
28 med to investigate whether detecting diffuse myocardial disease by T1 mapping can discriminate betwee
29 ardiomyopathy (ARVC) is an inherited genetic myocardial disease characterized by fibrofatty replaceme
30 tum cardiomyopathy is a pregnancy-associated myocardial disease characterized by the development of h
31 ), interventions reducing the progression of myocardial disease could affect survival.
32 c obstructive cardiomyopathy is an inherited myocardial disease defined by cardiac hypertrophy (wall
33 d wild-type mice matched for the severity of myocardial disease further confirmed that pericarditis,
34 sts that assess for subclinical coronary and myocardial disease have low sensitivity, and altered hem
35 nt insights into molecular genetic causes of myocardial diseases have highlighted the importance of s
36 ents with cardiomyopathy due to infiltrative myocardial diseases, HIV infection, or doxorubicin thera
37 etic resonance, subclinical inflammation and myocardial disease in asymptomatic HIV-infected individu
38    T2 mapping delineated a greater extent of myocardial disease in both conditions compared with that
39  role for T1 mapping in detection of diffuse myocardial disease in early disease stages and complemen
40 ors for coronary artery disease or different myocardial diseases in the absence of angiographically d
41                                      Diffuse myocardial disease is a characteristic feature in HCM, a
42                                              Myocardial disease manifesting predominantly as cardiomy
43 ntricular cardiomyopathy (ARVC) is a primary myocardial disease of incompletely resolved pathogenesis
44 ted cardiomyopathy (IDC) is a common primary myocardial disease of unknown etiology characterized by
45 e a family history of syncope, sudden death, myocardial disease or arrhythmias.
46 h patients (n=36) diagnosed with restrictive myocardial disease or severe tricuspid regurgitation aft
47 ancies in the association of enterovirus and myocardial disease, partially due to lack of data on the
48 th non-CMR-based imaging, a new or alternate myocardial disease process may be identified in half of
49 icates that microRNAs (miRs) are involved in myocardial disease processes, we also investigated wheth
50 revealed that such compromise was related to myocardial disease (related to hypertension, stiff vesse
51 re also present in patients with restrictive myocardial disease (RMD).
52 g is useful in diagnosing acute inflammatory myocardial diseases, such as myocarditis and tako-tsubo
53 ghlighting unique features of NMD-associated myocardial disease that require clinicians to tailor the
54 rdiomyocyte proliferation may be involved in myocardial diseases that affect this population, and tha
55 cardiomyopathies are a heterogenous group of myocardial diseases that vary according to pathogenesis,
56 pathy and atrial myopathy as contributors to myocardial disease warrant incorporation of aortic and a
57 d displays to evaluate the extent of CAD and myocardial disease was assessed, and utility of coregist
58                                              Myocardial disease was detected in 40% of cases, includi
59                                     Relevant myocardial disease was identified in 51% of patients usi
60 oung athletes (</= 35 years of age), whereas myocardial disease was more common in older individuals.
61  fibroblasts are a source of NO inflammatory myocardial diseases, we have studied the effect of cytok
62 new light on the emerging role of T cells in myocardial diseases, which primarily affect the elderly
63                      Gene therapy for common myocardial diseases will require effective and homogeneo
64 ardiomyopathy is a genetically heterogeneous myocardial disease with >1000 causal variants identified
65 pertrophic cardiomyopathy (HCM) is a primary myocardial disease with a prevalence of 1 in 500 in huma
66 diomyopathy (PPCM) is a pregnancy-associated myocardial disease with marked left ventricular systolic
67 ction delay is associated with more advanced myocardial disease, worse left ventricular (LV) function

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。